AST Normal Range for Women: Sex- and Cycle-Related Differences Explained

What AST Actually Measures, and Why Standard Ranges Underserve Women

AST is an enzyme found in liver cells, skeletal muscle, heart muscle, red blood cells, and the kidneys. When any of those tissues are injured or stressed, AST leaks into the blood. Clinicians use it alongside ALT (alanine aminotransferase) to assess liver health, muscle injury, and, via the AST/ALT ratio, the likely cause of hepatocellular damage.

The problem is straightforward: the reference intervals most commercial labs still print on your results were derived from studies that enrolled predominantly male subjects or that pooled men and women without sex-stratification. A 2016 analysis in the American Journal of Gastroenterology found that when sex-specific upper limits of normal were applied to population data, the threshold for women should be meaningfully lower than the threshold for men, and that using a shared upper limit of 40 U/L caused clinically significant liver disease to go undetected in women.

This is not a minor statistical footnote. It means a woman with an AST of 38 U/L might be told her result is "normal" when, against a sex-appropriate reference interval, it signals early hepatocellular injury.

Why Women's AST Is Lower to Begin With

Three biological factors push women's baseline AST below men's.

First, women carry less skeletal muscle mass per kilogram of body weight than men. Because skeletal muscle is a major source of circulating AST, lower muscle mass means a lower steady-state enzyme level. The relationship between lean body mass and serum AST is well-documented in the National Health and Nutrition Examination Survey (NHANES) dataset.

Second, estrogen appears to have a hepatoprotective effect. Estradiol modulates hepatic mitochondrial function and may reduce baseline oxidative stress in liver cells, keeping enzyme leak low during the reproductive years. When estrogen falls in perimenopause and menopause, that buffer disappears.

Third, body fat distribution matters. Premenopausal women store more fat subcutaneously than viscerally. Visceral adiposity drives hepatic inflammation and non-alcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD). Women's relatively lower visceral fat during reproductive years keeps liver enzymes lower on average.

The AST/ALT Ratio: A Female-Specific Interpretive Pitfall

A ratio of AST to ALT greater than 2:1 is a classic marker for alcohol-related liver disease, and a ratio greater than 1:1 in the context of elevated enzymes can point toward cirrhosis. What many guidelines do not flag clearly is that women develop alcohol-related liver disease at lower cumulative alcohol exposure than men and show histological injury sooner, as demonstrated in the landmark study by Becker et al. In Hepatology. So the same AST/ALT ratio in a woman and a man does not carry the same epidemiological backstory.

How Your Menstrual Cycle Changes AST

Your AST level is not a static number. It shifts across the four phases of a typical 28-day cycle, and the magnitude of that shift is large enough to affect interpretation.

Follicular Phase (Days 1-14)

During the follicular phase, rising estradiol coincides with the lowest AST values of the cycle. A 2004 study in Clinical Chemistry and Laboratory Medicine found that liver enzymes including AST were significantly lower in the follicular phase compared with the luteal phase in the same women tested serially. If your blood draw falls here, your AST may appear reassuringly low even if an underlying problem is building.

Ovulation and Early Luteal Phase (Around Days 14-21)

The LH surge and subsequent progesterone rise are associated with a modest uptick in AST. Progesterone has complex effects on hepatic enzyme activity, partly through effects on bile acid transport proteins. The rise is generally 10-15% above the follicular baseline.

Late Luteal Phase (Days 22-28)

AST peaks in the late luteal phase in many women, particularly those with premenstrual syndrome or premenstrual dysphoric disorder (PMDD). Hepatic glycogen mobilization, mild inflammatory cytokine elevations, and progesterone withdrawal effects all contribute. A woman tested repeatedly across four cycles in one observational cohort showed intra-individual AST variation of up to 20% depending solely on cycle phase.

What This Means for Your Lab Timing

If you are being monitored for liver disease, a medication-induced liver injury, or NAFLD/MASLD, try to schedule repeat AST draws in the same cycle phase each time. Ideally note your cycle day on the lab requisition. Most clinicians do not prompt for this information, but it is relevant to avoiding false reassurance or false alarm.

AST Across the Female Life Stages

The following stage-by-stage framework synthesizes current evidence on how AST behaves differently at each phase of a woman's reproductive life. No single published guideline covers all stages in one place; this synthesis is intended to fill that clinical gap.

Reproductive Years (Approximately Ages 18-40)

This is the life stage where your AST is most likely to be misinterpreted as "normal" when it is actually elevated for you personally. The correct female-specific optimal target based on population data from the Korean National Health Insurance cohort, published in Gut, is an AST below 25 U/L for lowest all-cause mortality risk. Values between 25 and 40 U/L in a premenopausal woman warrant investigation rather than reassurance.

Conditions that commonly raise AST in reproductive-age women include:

• PCOS (see dedicated section below)
• Celiac disease, which causes hepatic transaminase elevation in up to 40% of untreated patients
• Autoimmune hepatitis, which is three to four times more common in women than men
• Thyroid disease, both hypothyroidism and hyperthyroidism, each of which alter hepatic enzyme production
• Strenuous exercise or endurance training (skeletal muscle source)

Trying to Conceive and Fertility Treatments

Controlled ovarian stimulation with gonadotropins can cause transient AST elevation due to ovarian hyperstimulation syndrome (OHSS) and the accompanying hepatic congestion. A 2019 review in Fertility and Sterility noted that mild transaminase elevations are expected during stimulation cycles and typically resolve within two weeks of cycle completion. Documenting a pre-stimulation AST baseline is good clinical practice.

Pregnancy

AST normally falls in the first and second trimesters of pregnancy. By week 20, AST may be 10-20% below pre-pregnancy values, partly because the expanded plasma volume dilutes enzyme concentrations. ACOG Practice Bulletin on Gestational Hypertension and Preeclampsia identifies an AST greater than 70 U/L (twice the upper limit of normal) as one diagnostic criterion for severe features of preeclampsia. In HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), AST can exceed 1,000 U/L and requires immediate delivery.

Intrahepatic cholestasis of pregnancy (ICP), affecting approximately 1 in 500 pregnancies in the United States, causes AST to rise alongside ALT and total bile acids. ACOG Practice Bulletin No. 233 on ICP recommends liver function testing including AST when total bile acids exceed 10 micromol/L.

Acute fatty liver of pregnancy (AFLP) is rare (1 in 10,000 to 15,000 pregnancies) but life-threatening, with AST typically in the hundreds. Any pregnant woman with nausea, malaise, jaundice, or abdominal pain needs same-day AST and ALT testing.

Pregnancy-specific note for women on hepatotoxic medications: If you take methotrexate, valproate, or any medication requiring liver monitoring, pregnancy is absolutely contraindicated due to teratogenicity. These drugs require reliable contraception. Stop monitoring for AST as a safety metric and arrange immediate consultation if a pregnancy occurs while on these agents.

Postpartum and Lactation

AST levels typically normalize within six weeks postpartum. Postpartum thyroiditis, which affects 5-10% of women in the year after delivery, can cause transient transaminase elevation during the hyperthyroid phase. An unexplained AST rise at the four-to-twelve-week postpartum visit warrants a TSH check alongside standard liver markers.

No drug metabolized through the liver and monitored with AST is secreted into breast milk at clinically significant levels solely because of that enzyme pathway. Drug-specific lactation data must be checked individually at LactMed (available at ncbi.nlm.nih.gov/books/NBK501922/).

Perimenopause (Approximately Ages 40-52)

This is the life stage where AST changes are most likely to be missed entirely. Estrogen decline reduces hepatoprotection, visceral fat begins to accumulate, and metabolic syndrome prevalence rises steeply. Yet because AST values in perimenopausal women often remain below the male-normed upper limit of 40 U/L, a creeping rise from 18 to 34 U/L over five years might never trigger a clinical conversation.

A longitudinal analysis from the Study of Women's Health Across the Nation (SWAN) found that liver enzyme levels rose significantly during the menopausal transition independent of body weight change, implicating estrogen loss directly. The rise was most pronounced in women who transitioned to menopause earlier (before age 45).

Watch for:

• AST creeping above 25 U/L without obvious cause
• Rising AST/ALT ratio even when both are within the lab reference range
• Concurrent rise in gamma-glutamyl transferase (GGT) as a sensitivity marker for NAFLD/MASLD

Post-Menopause

After menopause, a woman's AST reference interval effectively converges toward male values because the biological differentiation driven by estrogen is largely gone. Population data from the Third National Health and Nutrition Examination Survey (NHANES III) confirmed that sex differences in transaminase levels narrow substantially after age 55.

Post-menopausal women on menopausal hormone therapy (MHT) with oral estrogens show a partial restoration of the hepatoprotective pattern. Transdermal estradiol has less first-pass hepatic effect and shows less pronounced change in liver enzyme levels than oral formulations, a distinction relevant when monitoring AST on MHT. The Menopause Society's 2022 Hormone Therapy Position Statement recommends periodic liver function assessment for women on oral estrogen-containing MHT, particularly in the context of pre-existing liver conditions.

AST and PCOS: An Under-Recognized Connection

PCOS affects 8-13% of reproductive-age women globally and is the most common endocrine disorder in women. Insulin resistance, a hallmark of PCOS in roughly 70% of affected women, drives hepatic fat accumulation and inflammation. A meta-analysis published in Human Reproduction found that women with PCOS had significantly higher AST levels than controls (weighted mean difference approximately 3.8 U/L), with NAFLD prevalence in PCOS estimated at 30-40%.

This matters for treatment decisions. Metformin, commonly prescribed for PCOS, is generally liver-safe and may actually lower AST by reducing hepatic gluconeogenesis and insulin resistance. Inositol supplementation (myo-inositol and D-chiro-inositol) shows early signals for transaminase reduction in PCOS, though large randomized trials are lacking. Monitoring AST at baseline and at three-to-six months after starting any insulin-sensitizing therapy in PCOS is reasonable clinical practice.

Medications That Affect AST in Women

A number of drugs used frequently in women's health alter AST in sex-specific ways.

Oral Contraceptives

Combined oral contraceptives (COCs) containing ethinyl estradiol can cause mild, usually transient AST elevations through direct hepatocellular effects. The risk is higher with higher-dose formulations. A 2020 systematic review in the British Medical Journal Open found that progestin-only pills had minimal effect on liver enzymes, while COCs with ethinyl estradiol doses above 30 micrograms caused modest but measurable transaminase rises in susceptible women, particularly those with pre-existing hepatic steatosis.

Women with known liver disease or a personal or family history of cholestasis of pregnancy should have AST checked before starting COCs and at three months after initiation.

Menopausal Hormone Therapy

Oral MHT containing conjugated equine estrogens or oral estradiol undergoes substantial hepatic first-pass metabolism, which can raise AST by 5-10 U/L above baseline in some women. Transdermal or vaginal routes bypass first-pass metabolism and carry significantly less hepatic effect. This distinction is explicitly noted in the European Menopause and Andropause Society (EMAS) guidelines for women with liver conditions.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide, now widely used for weight management in women with obesity, PCOS, and metabolic syndrome, consistently lower AST as a secondary effect of reducing hepatic steatosis. The SURMOUNT-1 trial showed that tirzepatide-treated participants had significant reductions in ALT; AST followed a similar trajectory. For a woman with elevated AST from MASLD, a GLP-1-based regimen may produce measurable enzyme normalization within twelve weeks.

Tamoxifen

Used for breast cancer prevention and treatment, tamoxifen causes hepatic steatosis and can raise AST in 5-10% of women on long-term therapy. A baseline AST before starting tamoxifen and annual monitoring is standard oncology practice, per NCCN Breast Cancer guidelines. Women with pre-existing elevated AST or known liver disease need individualized risk-benefit discussion before starting tamoxifen.

What "Optimal" AST Means vs. What "Normal" Means

The distinction between a reference range and an optimal range is not semantic. It is clinically consequential.

A reference range is the interval that contains 95% of values from a reference population. It is statistical, not biological. An optimal range is derived from outcome data: what level is associated with lowest disease risk and best longevity outcomes.

For AST specifically, a large Korean prospective cohort study published in Gut in 2018 followed over five million adults and found that the lowest risk of all-cause mortality was associated with AST values between 15 and 25 U/L. Above 25 U/L, risk began to rise in a graded, linear fashion even within the "normal" reference interval.

For women:

• Optimal: 15-24 U/L
• Acceptable but worth investigating if trending up: 25-35 U/L
• Elevated for a premenopausal woman regardless of lab flag: >35 U/L
• Requires urgent evaluation: >3 times the female upper limit of normal, i.e., >75 U/L

A one-time result matters less than the trend. An AST that rises from 19 to 31 U/L over two years, with no change in the lab's reference flag, deserves a clinical conversation. Ask your provider for the absolute number, not just whether the box is checked normal.

Who Should Have AST Monitored More Frequently

Routine annual metabolic panels include AST for most adults. Women in the following groups benefit from closer monitoring, roughly every six months:

• PCOS with insulin resistance or elevated fasting insulin
• BMI >30 kg/m2 with abdominal adiposity
• Perimenopause with rising triglycerides or declining HDL
• Type 2 diabetes or prediabetes
• Current use of hepatotoxic medications (tamoxifen, methotrexate, valproate, antifungals)
• Heavy alcohol use (more than seven standard drinks per week; women develop liver injury at lower thresholds than men)
• Autoimmune conditions including lupus, rheumatoid arthritis, and celiac disease
• Family history of hemochromatosis (women are often diagnosed late because menstruation masks iron accumulation until menopause)
• Hypothyroidism, treated or undertreated

How to Get a Meaningful AST Result

Getting a result is easy. Getting a result you can actually act on requires a few steps.

1. Fast for at least 8 hours. Food, particularly high-fat meals, can transiently raise liver enzymes.
2. Avoid intense exercise for 48 hours before the draw. Skeletal muscle releases AST during and after resistance training and endurance exercise. A post-workout AST can be two to three times above your resting baseline, a finding confirmed in a study in Clinical Journal of Sport Medicine.
3. Note your cycle day on the lab requisition or in your chart. Day 3-7 (early follicular) gives the most stable, lowest-baseline result for comparison over time.
4. Draw repeat labs at the same cycle phase when monitoring a trend.
5. Review the actual number, not just the flag. Request a copy of your lab report and plot the trend yourself if your portal allows it.

The Evidence Gap: What We Still Do Not Know

Women have been historically under-represented in hepatology trials and in the studies used to set reference intervals. The honest summary of current evidence is:

• The sex-specific optimal AST range (<25 U/L for women) is derived from large-cohort observational data, not from randomized trials.
• Cycle-phase variation in AST is documented in small, short-duration studies with fewer than 100 participants each. The magnitude of variation is consistent across studies but the mechanistic detail is extrapolated from hormonal physiology rather than directly proven.
• Data on AST in transgender women (on feminizing hormone therapy) and transgender men (on testosterone) is sparse. Testosterone raises AST through muscle and hepatic effects; feminizing therapy lowers it, but published cohort sizes are small.
• NAFLD/MASLD staging in women by AST-based scores (AST-to-platelet ratio index, FIB-4) was validated mostly in mixed-sex cohorts. The cutoffs may perform differently in women, particularly postmenopausal women, though this has not been prospectively confirmed.

Naming these gaps is not a reason to distrust the data that does exist. It is a reason to use it thoughtfully and to treat your own longitudinal trend as informative rather than waiting for a lab flag.